Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



GSK to Shed Weight Loss Drug alli and 18 Others

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

GlaxoSmithKline (NYSE: GSK  ) weight loss drug alli and 18 other over-the-counter products will be sold as the pharmaceutical giant pares down its consumer health-care business.

London-based GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, said Thursday that it will begin talking with potential buyers of those products in the next few weeks with the goal of divesting them by the end of the year, depending on buyer interest. Other products identified include analgesics Solpadeine, vitamin and supplement product Abtei, and feminine hygiene treatment Lactacyd.

GSK had announced its plans to divest "non-core consumer assets" in February when it discussed its fourth-quarter 2010 financial results. The consumer OTCs being put up for sale comprised just 10 percent of the company's consumer health-care revenue. GSK said it is not abandoning consumer products but will instead focus on fast-growing "priority brands" as well as products sold in emerging markets. The OTCs being divested are sold primarily in Europe and the United States.

Going forward, GSK's consumer efforts will now focus on oral health, over-the-counter wellness products, and nutrition. In those categories, GSK owns market-leading products in areas such as smoking control, dental sensitivity, and nutrition.

GlaxoSmithKline is a Motley Fool Global Gains pick. The Fool owns shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1476191, ~/Articles/ArticleHandler.aspx, 10/25/2016 1:16:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 18,223.03 77.32 0.43%
S&P 500 2,151.33 10.17 0.47%
NASD 5,309.83 52.43 1.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 4:02 PM
GSK $40.68 Down -0.45 -1.09%
GlaxoSmithKline CAPS Rating: ***